# Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT00378573** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 17 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** gemcitabine
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00378573
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Incidence of GI Perforation
- **Last updated:** 2010-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00378573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00378573, "Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00378573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*